Hyperprogressive disease: recognizing a novel pattern to improve patient management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 12, Pages 748-762
Publisher
Springer Nature America, Inc
Online
2018-10-25
DOI
10.1038/s41571-018-0111-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy
- (2018) Lee Ratner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation
- (2018) Feliciano Barrón et al. Journal of Thoracic Disease
- Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
- (2018) Marjorie Faure et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
- (2017) Solange Peters et al. Journal of Thoracic Oncology
- Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
- (2017) Esra A. Akbay et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
- (2017) Julia Wilkerson et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence
- (2017) Tatsuya Yoshida et al. MEDICAL ONCOLOGY
- Cancer immunotherapy: The dark side of PD-1 receptor inhibition
- (2017) Aya Ludin et al. NATURE
- Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling
- (2017) Kai Yang et al. NATURE
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
- (2017) George S. Karagiannis et al. Science Translational Medicine
- Neutrophils dominate the immune cell composition in non-small cell lung cancer
- (2017) Julia Kargl et al. Nature Communications
- Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
- (2017) Roman Groisberg et al. Journal for ImmunoTherapy of Cancer
- 1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST
- (2017) O. Bohnsack et al. ANNALS OF ONCOLOGY
- Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases: Table 1.
- (2016) O. Kanai et al. ANNALS OF ONCOLOGY
- Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization
- (2016) Lise Boussemart et al. CANCER RESEARCH
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity
- (2016) Deshapriya S. Karunarathne et al. IMMUNITY
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
- (2016) Marco De Simone et al. IMMUNITY
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
- (2016) Roger P. A’Hern JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
- (2016) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in Nonsquamous Non–Small-Cell Lung Cancer
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease
- (2016) Shunsuke Sakai et al. PLoS Pathogens
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
- (2016) Xinqi Wu et al. Cancer Immunology Research
- Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors
- (2016) Krijn K. Dijkstra et al. JAMA Oncology
- Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
- (2015) Megan A McNamara et al. BMC CANCER
- IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
- (2015) Z. Sun et al. CANCER RESEARCH
- Differential control of CD4+ T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma
- (2015) Jaclyn W. McAlees et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma
- (2015) Roberto Iacovelli et al. EUROPEAN UROLOGY
- Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells
- (2015) Pamela M. Odorizzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report
- (2015) Wouter W. Mellema et al. LUNG CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Vemurafenib-induced progression of breast cancer: a case report and review of the literature
- (2015) Aleksei V. Novik et al. Targeted Oncology
- T cell exhaustion during persistent viral infections
- (2015) Shannon M. Kahan et al. VIROLOGY
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia
- (2015) Cristina Peligero et al. PLoS Pathogens
- Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha – can tumor immune escape after immunotherapy accelerate disease progression?
- (2015) Örjan Strannegård et al. OncoImmunology
- TGR Analysis in Phase I Clinical Trials--Response
- (2014) C. Ferte et al. CLINICAL CANCER RESEARCH
- PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells
- (2014) Kristofor K. Ellestad et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Progression ofKRASmutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma
- (2014) A. Grey et al. INTERNAL MEDICINE JOURNAL
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3
- (2014) C. A. Fielding et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
- (2013) T. Powles et al. ANNALS OF ONCOLOGY
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
- (2013) K. Sharpe et al. CLINICAL CANCER RESEARCH
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
- (2013) C. Ferte et al. CLINICAL CANCER RESEARCH
- Induction, control, and plasticity of Treg cells: The immune regulatory network revised?
- (2013) Vincenzo Barnaba et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data
- (2013) Charles Ferté et al. EUROPEAN UROLOGY
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer
- (2013) Hua-Jun Chen et al. PATHOLOGY & ONCOLOGY RESEARCH
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
- (2012) A. W. Griffioen et al. CLINICAL CANCER RESEARCH
- Analyzing the Pivotal Trial That Compared Sunitinib and IFN- in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
- (2012) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3 Pathway Controls Regulatory and Effector T Cell Balance during Hepatitis C Virus Infection
- (2012) J. P. Moorman et al. JOURNAL OF IMMUNOLOGY
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
- (2012) John Dulos et al. JOURNAL OF IMMUNOTHERAPY
- Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib
- (2012) Oana Pop et al. Journal of Thoracic Oncology
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
- (2012) Jin-Ji Yang et al. LUNG CANCER
- The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
- (2012) Peter T Sage et al. NATURE IMMUNOLOGY
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiation-Induced Reprogramming of Breast Cancer Cells
- (2012) Chann Lagadec et al. STEM CELLS
- Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells
- (2011) Christine Bourcier et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape
- (2011) E. di Tomaso et al. CANCER RESEARCH
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Tumour growth rates and RECIST criteria in early drug development
- (2011) Carlos Gomez-Roca et al. EUROPEAN JOURNAL OF CANCER
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs
- (2010) Yenkel Grinberg-Bleyer et al. JOURNAL OF CLINICAL INVESTIGATION
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
- (2010) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases
- (2009) Ingrid M. E. Desar et al. ACTA ONCOLOGICA
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
- (2009) Pascal Wolter et al. ACTA ONCOLOGICA
- Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
- (2009) R. Karim et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Bone Scan Flare Phenomenon in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
- (2009) Heng-Sheng Chao et al. CLINICAL NUCLEAR MEDICINE
- The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE
- (2009) Alla L. Zozulya et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV
- (2009) Debora Franceschini et al. JOURNAL OF CLINICAL INVESTIGATION
- Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL ONCOLOGY
- IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
- (2009) B. Baban et al. JOURNAL OF IMMUNOLOGY
- The effects of surgery on tumor growth: a century of investigations
- (2008) R. Demicheli et al. ANNALS OF ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells
- (2008) H. J. P. M. Koenen et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation
- (2008) Thomas Lehner IMMUNOLOGY
- CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I–αβTCR interaction and become IL-10-producing active regulatory cells
- (2008) Muhaimin Rifa'i et al. INTERNATIONAL IMMUNOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started